FATE THERAPEUTICS INC Sale of Stock, Consideration Received on Transaction
FATE THERAPEUTICS INC (FATE) reported Sale of Stock, Consideration Received on Transaction of $74.50 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2024-11-12
- FATE THERAPEUTICS INC sale of stock, consideration received on transaction for the quarter ending 2024-03-31 was $74.50M.
- FATE THERAPEUTICS INC sale of stock, consideration received on transaction for the quarter ending 2018-12-31 was $779.00K, a 2260.61% increase year-over-year.
- FATE THERAPEUTICS INC sale of stock, consideration received on transaction for the quarter ending 2018-09-30 was $1.13M, a 968.87% increase year-over-year.
- FATE THERAPEUTICS INC sale of stock, consideration received on transaction for the quarter ending 2018-06-30 was $175.00K, a 446.88% increase year-over-year.
- FATE THERAPEUTICS INC sale of stock, consideration received on transaction for fiscal 2018 was $2.69M, a 1213.66% increase from fiscal 2017.
- FATE THERAPEUTICS INC sale of stock, consideration received on transaction for fiscal 2017 was $205.00K, a 10.22% increase from fiscal 2016.
- FATE THERAPEUTICS INC sale of stock, consideration received on transaction for fiscal 2016 was $186.00K, a 55.71% decline from fiscal 2015.
- FATE THERAPEUTICS INC sale of stock, consideration received on transaction for fiscal 2015 was $420.00K, a 195.77% increase from fiscal 2014.
| Period end | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 3 month as first filed | Sale of Stock, Consideration Received on Transaction 6 month | Sale of Stock, Consideration Received on Transaction 9 month | Sale of Stock, Consideration Received on Transaction 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $74.50M 10-Q · filed 2024-11-12 | $74.70M 10-Q · filed 2024-05-09 | |||
| 2018-12-31 | $779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $1.91M derived: sum of 2 quarters · filed 2019-03-05 | $2.09M derived: sum of 3 quarters · filed 2019-03-05 | $2.69M 10-K · filed 2019-03-05 | |
| 2018-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $1.31M derived: sum of 2 quarters · filed 2018-11-01 | $1.91M 10-Q · filed 2018-11-01 | $1.95M derived: sum of 4 quarters · filed 2019-03-05 | |
| 2018-06-30 | $175.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $781.00K 10-Q · filed 2018-08-06 | $814.00K derived: sum of 3 quarters · filed 2019-03-05 | $920.00K derived: sum of 4 quarters · filed 2019-03-05 | |
| 2018-03-31 | $606.00K 10-Q · filed 2018-05-10 | $639.00K derived: sum of 2 quarters · filed 2019-03-05 | $745.00K derived: sum of 3 quarters · filed 2019-03-05 | $777.00K derived: sum of 4 quarters · filed 2019-03-05 | |
| 2017-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $139.00K derived: sum of 2 quarters · filed 2019-03-05 | $171.00K derived: sum of 3 quarters · filed 2019-03-05 | $205.00K 10-K · filed 2019-03-05 | |
| 2017-09-30 | $106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $138.00K derived: sum of 2 quarters · filed 2018-11-01 | $172.00K 10-Q · filed 2018-11-01 | $191.00K derived: sum of 4 quarters · filed 2019-03-05 | |
| 2017-06-30 | $32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $66.00K 10-Q · filed 2018-08-06 | $85.00K derived: sum of 3 quarters · filed 2019-03-05 | $109.00K derived: sum of 4 quarters · filed 2019-03-05 | |
| 2017-03-31 | $34.00K 10-Q · filed 2018-05-10 | $53.00K derived: sum of 2 quarters · filed 2019-03-05 | $77.00K derived: sum of 3 quarters · filed 2019-03-05 | $73.00K derived: sum of 4 quarters · filed 2019-03-05 | |
| 2016-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $43.00K derived: sum of 2 quarters · filed 2019-03-05 | $39.00K derived: sum of 3 quarters · filed 2019-03-05 | $186.00K 10-K · filed 2019-03-05 | |
| 2016-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $20.00K derived: sum of 2 quarters · filed 2017-11-01 | $167.00K 10-Q · filed 2017-11-01 | $202.00K derived: sum of 4 quarters · filed 2018-03-05 | |
| 2016-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $143.00K 10-Q · filed 2017-08-14 | $178.00K derived: sum of 3 quarters · filed 2018-03-05 | $399.00K derived: sum of 4 quarters · filed 2018-03-05 | |
| 2016-03-31 | $147.00K 10-Q · filed 2017-05-15 | $182.00K derived: sum of 2 quarters · filed 2018-03-05 | $403.00K derived: sum of 3 quarters · filed 2018-03-05 | $492.00K derived: sum of 4 quarters · filed 2018-03-05 | |
| 2015-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $256.00K derived: sum of 2 quarters · filed 2018-03-05 | $345.00K derived: sum of 3 quarters · filed 2018-03-05 | $420.00K 10-K · filed 2018-03-05 | |
| 2015-09-30 | $221.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $310.00K derived: sum of 2 quarters · filed 2016-11-07 | $385.00K 10-Q · filed 2016-11-07 | $381.00K derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | $89.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $164.00K 10-Q · filed 2016-08-08 | $160.00K derived: sum of 3 quarters · filed 2017-03-16 | $162.00K derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-03-31 | $75.00K 10-Q · filed 2016-05-09 | $71.00K derived: sum of 2 quarters · filed 2017-03-16 | $73.00K derived: sum of 3 quarters · filed 2017-03-16 | ||
| 2014-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$2.00K derived: sum of 2 quarters · filed 2017-03-16 | $142.00K 10-K · filed 2017-03-16 | ||
| 2014-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $146.00K 10-Q · filed 2015-11-03 | |||
| 2014-06-30 | $144.00K 10-Q · filed 2015-08-05 | ||||
| 2013-12-31 | $23.00K 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |